Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Im, Seock‐Ah; Lu, Yen‐Shen; Bardia, Aditya; Harbeck, Nadia; Colleoni, Marco; Franke, Fábio; W.C. Chow, Louis; Sohn, Joohyuk; Lee, Keun-Seok; Campos-Gómez, Saúl; Villanueva-Vázquez, Rafael; Jung, Kyung-Hae; Chakravartty, Arunava; Hughes, Gareth; Gounaris, Ioannis; Rodriguez-Lorenc, Karen; Taran, Tetiana; A. Hurvitz, Sara; Tripathy, Debu

doi:10.1056/nejmoa1903765

Public

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Published in New England Journal of Medicine • Jun 4, 2019

Authors:

Seock‐Ah Im

Yen‐Shen Lu

Aditya Bardia

Abstract

BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients wit...

Subject

Medicine

Hazard ratio

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!